2 completed, 2 not yet recruiting, 2 recruiting, 1 active not recruiting. 4 Phase 1, 3 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 2 | 3 | Completed 2, Active not recruiting 1 |
| Phase 3 | 3 | Recruiting 2, Not yet recruiting 1 |
Follow Norroy Bioscience Co., LTD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Safety, Pharmacokinetics, Distribution，Radiation Safety and Sensitivity/Specificity of PET/CT Imaging With 68Ga-NYM096 in Participants With IRM 68Ga-NYM096 injection - Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 | Not yet recruiting | Norroy Bioscience Co., LTD | 20 | 2026-09-01 | 2026-08-17 |
| Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) 177Lu-NYM032 injection, Best supportive/best standard of care - Prostate Cancer | Phase 3 | Not yet recruiting | Norroy Bioscience Co., LTD | 600 | 2026-08-31 | 2026-08-31 |
| This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer. 68-Ga-NYM032 - Prostate Cancer | Phase 3 | Recruiting | Norroy Bioscience Co., LTD | 232 | 2026-08-31 | 2026-09-15 |
| Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer. 68-Ga-NYM032 - Prostate Cancer (Diagnosis) | Phase 3 | Recruiting | Norroy Bioscience Co., LTD | 365 | 2026-08-06 | 2026-08-17 |
| Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM005 in Patients 68Ga-NYM005 injection - Clear Cell Renal Cell Carcinoma Metastatic | Phase 1 / Phase 2 | Completed | Norroy Bioscience Co., LTD | 19 | 2024-06-17 | 2025-05-21 |
| Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM032 in Patients 68Ga-NYM032 injection - Prostate Cancer | Phase 1 / Phase 2 | Completed | Norroy Bioscience Co., LTD | 20 | 2024-06-04 | 2025-05-21 |
| A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC 177Lu-NYM032 injection - Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Active not recruiting | Norroy Bioscience Co., LTD | 30 | 2024-04-26 | 2025-05-21 |
Prostatic Neoplasms (4) · Carcinoma, Renal Cell (1) · Clear-cell metastatic renal cell carcinoma (1) · Disease (1)
China (5)
Chunjing Yu (1) · Li Huo, MD (1)